Literature DB >> 17583933

Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers.

Taufika Islam Williams1, Kristina L Toups, Diana A Saggese, Kimberly R Kalli, William A Cliby, David C Muddiman.   

Abstract

Cancer research in recent years has immensely benefited from the development of novel technologies that enable scientists to perform detailed investigations of genomes, transcriptomes, proteomes, and metabolomes. This has invariably furthered knowledge of tumorigenesis and etiology of cancer. The resulting information can, in the foreseeable future, effect a significant change in the pace of cancer research, thereby producing improvements in patient care. Ovarian cancer in particular has received the interest of the scientific community, being the most frequent cause of death from gynecological cancers, characterized by few early symptoms, diagnosis at an advanced stage, as well as poor prognosis. Ovarian cancer is a malignancy in which normal ovarian cells begin to grow in an uncontrolled, abnormal manner and produce tumors in one or both ovaries. Epithelial cancers, the most common ovarian cancers (>80%), develop from cells lining the ovarian surface. Most ovarian cancer research is primarily focused on the early detection and treatment of epithelial ovarian cancer, the more common ovarian malignancy. This review offers an introduction to ovarian cancer, with particular emphasis on human epithelial ovarian cancer. Current methods of detection and therapy are discussed. A survey of promising new protein, gene, and metabolite biomarkers on the horizon is provided. Future prospects for improved diagnosis are offered.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17583933     DOI: 10.1021/pr070041v

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  41 in total

1.  Microfluidic electrochemical immunoarray for ultrasensitive detection of two cancer biomarker proteins in serum.

Authors:  Bhaskara V Chikkaveeraiah; Vigneshwaran Mani; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  Biosens Bioelectron       Date:  2011-05-11       Impact factor: 10.618

Review 2.  Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer.

Authors:  James F Rusling; Challa V Kumar; J Silvio Gutkind; Vyomesh Patel
Journal:  Analyst       Date:  2010-07-08       Impact factor: 4.616

3.  Measuring the intra-individual variability of the plasma proteome in the chicken model of spontaneous ovarian adenocarcinoma.

Authors:  Adam M Hawkridge; Rebecca B Wysocky; James N Petitte; Kenneth E Anderson; Paul E Mozdziak; Oscar J Fletcher; Jonathan M Horowitz; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-07-17       Impact factor: 4.142

Review 4.  Nanomaterials-based electrochemical immunosensors for proteins.

Authors:  James F Rusling
Journal:  Chem Rec       Date:  2012-01-30       Impact factor: 6.771

5.  Confounding effects of hormone replacement therapy in protein biomarker studies.

Authors:  Sharon J Pitteri; Samir M Hanash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-29       Impact factor: 4.254

6.  Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification.

Authors:  Vigneshwaran Mani; Bhaskara V Chikkaveeraiah; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  ACS Nano       Date:  2009-03-24       Impact factor: 15.881

Review 7.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

8.  Single-wall carbon nanotube forest arrays for immunoelectrochemical measurement of four protein biomarkers for prostate cancer.

Authors:  Bhaskara V Chikkaveeraiah; Ashwin Bhirde; Ruchika Malhotra; Vyomesh Patel; J Silvio Gutkind; James F Rusling
Journal:  Anal Chem       Date:  2009-11-01       Impact factor: 6.986

9.  The effects of abundant plasma protein depletion on global glycan profiling using nanoLC FT-ICR mass spectrometry.

Authors:  Michael S Bereman; David C Muddiman
Journal:  Anal Bioanal Chem       Date:  2010-01-20       Impact factor: 4.142

10.  In-depth LC-MS/MS analysis of the chicken ovarian cancer proteome reveals conserved and novel differentially regulated proteins in humans.

Authors:  Angelito I Nepomuceno; Huanjie Shao; Kai Jing; Yibao Ma; James N Petitte; Michael O Idowu; David C Muddiman; Xianjun Fang; Adam M Hawkridge
Journal:  Anal Bioanal Chem       Date:  2015-07-10       Impact factor: 4.142

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.